Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Sep
23
Today In Oncology
Excess Mortality Halts Trial of Venetoclax Added to DA-EPOCH-R in Double-Hit Lymphoma
Germline EGFR T790M Associated With Significant Lung Cancer Risk
Second-Line Investigational Monoclonal Antibody in Metastatic Squamous NSCLC
Neoadjuvant Anbenitamab/Chemotherapy Combination Improves Response in ERBB2-Positive Breast Cancer
ASCO Breakthrough Studies Target Supportive Care Problems That Can Derail Treatment
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo